PropertyValue
?:abstract
  • A vaccine to protect against COVID-19 is urgently needed. Such a vaccine should efficiently induce high-affinity neutralizing antibodies which neutralize SARS-CoV-2, the cause of COVID-19. However, there is a concern regarding both vaccine-induced eosinophilic lung disease and eosinophil-associated Th2 immunopotentiation following infection after vaccination. Here, we review the anticipated characteristics of a COVID-19 vaccine to avoid vaccine-associated eosinophil immunopathology.
?:creator
?:doi
  • 10.1159/000509368
?:doi
?:journal
  • Int_Arch_Allergy_Immunol
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/55fdd9bbbab12162477893a0f1c48d8bbf1396cd.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7360494.xml.json
?:pmcid
?:pmid
?:pmid
  • 32544911.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection
?:type
?:year
  • 2020-06-16

Metadata

Anon_0  
expand all